Last C$1.27 CAD
Change Today +0.05 / 4.10%
Volume 26.5K
As of 3:59 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

aeterna zentaris inc (AEZ) Snapshot

Open
C$1.22
Previous Close
C$1.22
Day High
C$1.27
Day Low
C$1.22
52 Week High
05/16/13 - C$2.20
52 Week Low
11/20/13 - C$1.04
Market Cap
71.8M
Average Volume 10 Days
24.0K
EPS TTM
C$0.29
Shares Outstanding
56.5M
EX-Date
--
P/E TM
4.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for AETERNA ZENTARIS INC (AEZ)

Related News

No related news articles were found.

aeterna zentaris inc (AEZ) Related Businessweek News

No Related Businessweek News Found

aeterna zentaris inc (AEZ) Details

Aeterna Zentaris Inc., a specialty biopharmaceutical company, develops and commercializes novel treatments in oncology and endocrinology worldwide. The company’s product pipeline includes MACRILEN, a product candidate for which the company has filed a New Drug Application to the FDA as an oral product used for evaluating adult growth hormone deficiency; and is also investigated in Phase 2A clinical trials to treat cancer-induced cachexia. Its product pipeline also comprises Zoptarelin doxorubicin, which has completed Phase 2 clinical trials to treat ovarian and endometrial cancer, and breast cancer; and Phase 1/2 clinical trials to treat bladder and prostate cancers. In addition, the company’s product candidates in clinical and preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136 for oncology; and disorazol Z product candidates, such as AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.

Founded in 1990

aeterna zentaris inc (AEZ) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $328.8K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $331.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $122.0K
Compensation as of Fiscal Year 2013.

aeterna zentaris inc (AEZ) Key Developments

Aeterna Zentaris Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

Aeterna Zentaris Inc. announced consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, loss from operations was USD 7,972,000 against USD 8,119,000 a year ago. Loss before income taxes was USD 10,596,000 against USD 8,130,000 a year ago. Net loss from continuing operations was USD 10,596,000 or USD 0.28 per basic and diluted share against USD 8,130,000 or USD 0.34 per basic and diluted share a year ago. Net loss was USD 8,243,000 or USD 0.22 per basic and diluted share against USD 6,947,000 or USD 0.29 per basic and diluted share a year ago. The comparative quarter-over-quarter increase in net loss is mainly due to increased finance costs (primarily related to the change in fair value of warrant liability), partially offset by higher net income from discontinued operations (related to Cetrotide(r) manufacturing activities and the recognition of related deferred revenues) and lower operating expenses. For the year, revenue was USD 6,175,000 against USD 2,053,000 a year ago. This increase is attributable to the accelerated recognition of deferred revenues. Loss from operations was USD 27,476,000 against USD 29,736,000 a year ago. Loss before income taxes was USD 27,240,000 against USD 23,144,000 a year ago. Net loss from continuing operations was USD 27,240,000 or USD 0.92 per basic and diluted share against USD 23,144,000 or USD 1.17 per basic and diluted share a year ago. Net income was USD 6,815,000 or USD 0.24 per basic and diluted share against net loss of USD 20,412,000 or USD 1.03 per basic and diluted share a year ago. The comparative year-over-year decrease in net loss is mainly due to higher net income from discontinued operations and higher revenues, partially compensated by higher operating costs and lower finance income.

Aeterna Zentaris Mulls Acquisitions

Aeterna Zentaris Inc. (TSX:AEZ) is seeking acquisitions. Aeterna Zentaris will use part of its proceeds from the offering for the acquisitions purpose too. Aeterna Zentaris said, "Unless otherwise specified in a Prospectus Supplement, the net proceeds resulting from the issuance of Common Shares will be used for the general corporate purposes of Aeterna Zentaris, which may include the continued funding of the Company’s ongoing drug development activities, which, as of the date of this Prospectus, primarily includes the advancement of its zoptarelin doxorubicin program, the marketing and commercialization of MACRILEN™ (assuming the FDA issues final approval in the expected timeframe), the potential in-licensing or acquisition of new commercial products or other corporate and business development activities, and the potential expansion of existing product candidates into other indications."

Aeterna Zentaris Inc., Q4 2013 Earnings Call, Mar 21, 2014

Aeterna Zentaris Inc., Q4 2013 Earnings Call, Mar 21, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEZ:CN C$1.27 CAD +0.05

AEZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEZ.
View Industry Companies
 

Industry Analysis

AEZ

Industry Average

Valuation AEZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.0x
Price/Book 3.1x
Price/Cash Flow 9.6x
TEV/Sales 3.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETERNA ZENTARIS INC, please visit www.aezsinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.